Neuroimaging-guided immunotherapy for glioblastoma
Funded at University of Oklahoma · NIH-11269427 · Data updated 2026-11-12
A patient-facing overview of a project using advanced brain imaging to guide immunotherapy treatments for glioblastoma, aiming to improve how well these therapies work.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma NIH-funded |
| Lab location | 1 site (Norman, United States) |
| Project start | May 15, 2026 |
| Project end | January 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $210,086 |
| NIH project number | 1P20GM162339-01 |
| Project ID | NIH-11269427 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with glioblastoma who are candidates for anti-angiogenic therapy and related imaging monitoring.
✕Less likely to help
Patients whose tumors do not respond to anti-angiogenic approaches or who cannot undergo advanced imaging procedures.
What this research studies
This project will use state-of-the-art optical imaging to watch how glioblastoma tumors react to anti-angiogenesis therapies inside the brain over time. By combining high-resolution imaging with spatial gene information and machine learning, doctors hope to tailor treatments like anti-ELTD1 and OKN to each patient’s tumor. The goal is to understand why some tumors resist treatment and to adjust therapies before resistance develops. If successful, this approach could lead to more effective, personalized treatment plans and better survival for patients with this challenging cancer.
Why it matters
Potential benefit: Potentially more effective, personalized treatment options for glioblastoma, with improved monitoring of tumor response.
How similar studies have gone: Prior anti-angiogenic trials showed mixed results; this project seeks to improve outcomes through high-resolution imaging and data-driven treatment guidance.
Where this research is happening
-
University of Oklahoma
Norman, United States Active
Researchers
- Principal investigator: Miller, David Roger — University of Oklahoma
- Study coordinator: Miller, David Roger
Related research
Other NIH-funded projects on the same topics.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Understanding why some glioblastoma patients respond long-term to an ATL-DC vaccine
A study in glioblastoma patients exploring why a personalized vaccine made from a patient’s own tumor blood cells helps some people live longer.
-
Immunotherapy for Glioblastoma by Targeting a neuroimmune signal
A new approach aims to help people with glioblastoma by blocking a nerve-derived signal that keeps tumor-fighting immune cells from working well.
-
Tumor-fighting NK cells that target glioblastoma
A science team is testing engineered natural killer (NK) cells to better home in on and kill glioblastoma tumors in the brain.
-
Changing the glioblastoma tumor environment to boost immune therapy
This project tests whether blocking Wnt signaling together with PD‑1 immunotherapy can help people with glioblastoma by reducing immune‑suppressing cells and increasing tumor‑fighting immune cells.
-
Developing nanoparticles to enhance immune response against brain cancer
This study is exploring a new way to help fight glioblastoma, a tough type of brain cancer, by using tiny particles to deliver a special RNA that can boost the immune system's ability to attack the tumor, and it's being tested in mice to see how well it works.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.